NCT05275868CompletedPhase 1
Phase I study of MGY825 in patients with lung cancer
Source: EU CTIS (euclinicaltrials.eu) · Last updated 14 Jul 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (actual)
- First submitted
- 24 Nov 2023
- Start date
- 25 Nov 2022
- Lead sponsor
- Novartis Pharma AG
- Diseases
- Lung cancer
- NCT number
- NCT05275868
- EU CT number
- 2023-504350-36-00
- EudraCT number
- 2021-006793-22
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 50
- 5 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (5)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital Cologne AöR Coordinator of this site? Confirm its status | Cologne | Germany | Completed |
| Universitaetsklinikum Essen (AoR) Coordinator of this site? Confirm its status | Essen | Germany | Completed |
| Goethe University Frankfurt Coordinator of this site? Confirm its status | Frankfurt Am Main | Germany | Completed |
| Hospital Universitari Vall d'Hebron Coordinator of this site? Confirm its status | Barcelona | Spain | Completed |
| Hospital Universitario HM Sanchinarro Coordinator of this site? Confirm its status | Madrid | Spain | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.